{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T18:40:37Z","timestamp":1763059237973,"version":"3.38.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,21]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To elucidate the effectiveness of dapagliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, on renal function in patients with rheumatic musculoskeletal diseases complicated by chronic kidney disease (CKD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective analysis of patients with rheumatic musculoskeletal disease and chronic kidney disease who were treated with dapagliflozin for more than a year. The good response was defined as an improvement in the estimated glomerular filtration rate slope per year after dapagliflozin treatment compared to that before treatment. Additionally, we investigated the response rate and its predictive factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this analysis, 43 patients were included. The average estimated glomerular filtration rate slope demonstrated a significant improvement after dapagliflozin treatment compared to that before the treatment (0.04 vs \u22120.55\u2009ml\/min\/1.73\u2009m2\/year, P\u2009=\u2009.001). A good response rate was 69.8% and was associated with low average levels of C-reactive protein, a high frequency of angiotensin II receptor blocker (ARB) use, and a low frequency of tacrolimus use compared to nonresponse (0.08\u2009\u00b1\u20090.18 vs 0.25\u2009\u00b1\u20090.29\u2009mg\/dl, P\u2009=\u2009.03; 80.0 vs 38.4%, P\u2009=\u2009.01; 10.0 vs 76.9%, P\u2009&amp;lt;\u2009.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dapagliflozin is effective for rheumatic musculoskeletal disease patients with CKD for preventing deterioration of renal function. Antihypertensive treatment with ARB and inflammation control without tacrolimus was associated with a high likelihood of favourable response to dapagliflozin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roae090","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:43:56Z","timestamp":1728924236000},"page":"345-351","source":"Crossref","is-referenced-by-count":2,"title":["Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5172-1102","authenticated-orcid":false,"given":"Hironari","family":"Hanaoka","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9278-7751","authenticated-orcid":false,"given":"Kazuoto","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shutaro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-2088","authenticated-orcid":false,"given":"Yasushi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"2025030423303897500_R1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.iac.2022.10.006","article-title":"Autoimmune connective tissue diseases: systemic lupus erythematosus and rheumatoid arthritis","volume":"43","author":"Rose","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"2025030423303897500_R2","doi-asserted-by":"crossref","first-page":"c107","DOI":"10.1159\/000077372","article-title":"Renal disease as a predictor of increased mortality among patients with rheumatoid arthritis","volume":"96","author":"Sihvonen","year":"2004","journal-title":"Nephron Clin Pract"},{"key":"2025030423303897500_R3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1007\/s10067-007-0625-y","article-title":"Prognosis of clinical renal disease and incidence of new renal findings in patients with rheumatoid arthritis: follow-up of a population-based study","volume":"26","author":"Karstila","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2025030423303897500_R4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ackd.2006.04.006","article-title":"Infections and cardiovascular disease in patients with chronic kidney disease","volume":"13","author":"Foley","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025030423303897500_R5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1681\/ASN.2007070744","article-title":"The IL-6\/IL-6R axis plays a critical role in acute kidney injury","volume":"19","author":"Nechemia-Arbely","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2025030423303897500_R6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160225","article-title":"Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis","volume":"11","author":"Kochi","year":"2016","journal-title":"PLoS One"},{"key":"2025030423303897500_R7","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","article-title":"Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs","volume":"15","author":"Hanaoka","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025030423303897500_R8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108732","article-title":"SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases","volume":"24","author":"Di Costanzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025030423303897500_R9","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025030423303897500_R10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025030423303897500_R11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with the use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025030423303897500_R12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/annrheumdis-2022-222512","article-title":"SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection","volume":"81","author":"Morales","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025030423303897500_R13","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025030423303897500_R14","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025030423303897500_R15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma)","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2025030423303897500_R16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2025030423303897500_R17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025030423303897500_R18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025030423303897500_R19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2025030423303897500_R20","first-page":"424","article-title":"Preliminary criteria for classification of adult Still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2025030423303897500_R21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025030423303897500_R22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int"},{"key":"2025030423303897500_R23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10157-007-0463-x","article-title":"The prevalence of chronic kidney disease (CKD) in the Japanese population is predicted by the MDRD equation modified by a Japanese coefficient","volume":"11","author":"Imai","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"2025030423303897500_R24","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfg349","article-title":"A comparison between cystatin C, plasma creatinine, and the Cockcroft and Gault formula for the estimation of glomerular filtration rate","volume":"18","author":"Hoek","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025030423303897500_R25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","article-title":"A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors","volume":"33","author":"Sen","year":"2021","journal-title":"Cell Metab"},{"key":"2025030423303897500_R26","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025030423303897500_R27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (Dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"2025030423303897500_R28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","article-title":"DZI. Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition","volume":"146","author":"Lytvyn","year":"2022","journal-title":"Circulation"},{"key":"2025030423303897500_R29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ijcard.2014.11.031","article-title":"A review of clinical studies on angiotensin II receptor blockers and risk of cancer","volume":"177","author":"D\u00e9zsi","year":"2014","journal-title":"Int J Cardiol"},{"key":"2025030423303897500_R30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2025030423303897500_R31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomized controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025030423303897500_R32","first-page":"6","article-title":"Tacrolimus is effective for lupus nephritis patients with persistent proteinuria","volume":"28","author":"Uchino","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025030423303897500_R33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000524594","article-title":"Risk factors for nephrotoxicity due to tacrolimus therapy for ulcerative colitis","volume":"103","author":"Nakata","year":"2022","journal-title":"Digestion"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roae090\/59751515\/roae090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/2\/345\/59751515\/roae090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/2\/345\/59751515\/roae090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:31:00Z","timestamp":1741131060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/2\/345\/7816085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,9]]},"published-print":{"date-parts":[[2025,2,21]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roae090","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"type":"print","value":"1439-7595"},{"type":"electronic","value":"1439-7609"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,9]]}}}